Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics of patients with refractory Behcet uveitis

From: Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients

  Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age-range at onset (years) 20–30 40–50 20–30 30–40 30–40
Duration of IFNα2a treatment (months) 6 5 28 12 2
Overall follow-up period (months) 51 27 34 72 110
Laterality Bilateral Unilateral Bilateral Bilateral Bilateral
Anatomic classification of uveitis Panuveitis Panuveitis Panuveitis Panuveitis Panuveitis
Extraocular manifestations of BD Oral ulcer CNS involvement Epididymitis Arthritis Skin lesion (EN) Oral ulcer Genital ulcer Skin lesion(EN) GI involvement Oral ulcer Skin lesion (folliculitis) GI involvement Oral ulcer Skin lesion (EN) Oral ulcer Skin lesion(EN)
Previous immunosuppressive treatment Azathioprine 100 mg/d, Methotrexate 17.5 mg weekly Cyclosporine 200 mg/d Azathioprine 100 mg/d, Methotrexate 17.5 mg weekly Cyclosporine 200 mg/d, Azathioprine 100 mg/d Mycophenolate mofetil 2 g/d Mycophenolate mofetil 2 g/d
Dose of oral corticosteroid (mg/d prednisolone equivalent), preTx→postTx 40 → 10 15 → 0 20 → 0 40 → 5 15 → 0
Relapse rate (number of uveitis attacks/year), preTx→postTx 2.13 → 2 1.64 → 0 4.00 → 0 1.80 → 0 1.22 → 0
Response to IFNα2a No Yes Yes Yes Yes
Adverse events Flu-like Sx Depression Flu-like Sx Flu-like Sx Flu-like Sx Flu-like Sx
  1. BD: Behcet’s disease, CNS: central nervous system, EN: erythema nodosum, GI: gastrointestinal, IFNα2a: interferon alpha-2a, Sx: symptoms, Tx: treatment